Market Signal Briefing

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tronox To Contact Him Directly To Discuss Their Options

If you suffered losses in Tronox between February 2, 2025 and July 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tronox Holdings plc (“Tronox” or the “Company”) (NYSE: TROX) and reminds investors of the November 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing the Company’s revenue projections.

On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in TiO2 sales for the quarter. The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.” As a result of the setback in sales, defendants revised the Company’s 2025 financial outlook lowering its full-year revenue guidance and reducing its dividend by 60%.

Following this news, Tronox’s common stock declined dramatically. From a closing market price of $5.14 per share on July 30, 2025, Tronox’s stock price fell to $3.19 per share on July 31, 2025, a decline of about 38% in the span of just a single day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Tronox’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Tronox Holdings class action, go to www.faruqilaw.com/TROX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Molina To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Molina between February 5, 2025 and July 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 7, 2025, before the market opened, Molina issued a press release announcing financial results for the second quarter of 2025 and slashing full year 2025 adjusted earnings per share guidance. The press release revealed the Company’s second quarter 2025 adjusted earnings of approximately $5.50 per share, which was “below its prior expectations” due to “medical cost pressures in all three lines of business.” The Company announced it “expects these medical cost pressures to continue into the second half of the year” and cut guidance for expected adjusted earnings per share 10.2% at the midpoint, from “at least $24.50 per share” to a “range of $21.50 to $22.50 per share.” The press release revealed Molina was experiencing a “short-term earnings pressure” from a “dislocation between premium rates and medical cost trend which has recently accelerated.”

On this news, Molina’s stock price fell $6.97, or 2.9%, to close at $232.61 per share on July 7, 2025, on unusually heavy trading volume.

Then, on July 23, 2025, after the market closed, Molina issued a press release reporting its financial results for the second quarter ended June 30, 2025 and further slashing the Company’s full-year 2025 earnings guidance. The press release revealed, in part, that the Company’s “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year;” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share.” This represented another 13.6% cut to guidance of earnings per share at the midpoint, from the cut to guidance announced less than two weeks earlier. The Company also cut its guidance for its full year 2025 GAAP net income 27% to $912 million. The Company attributed its results a full year outlook to a “challenging medical cost trend environment,” including mere “utilization of behavioral health, pharmacy, and inpatient and outpatient services.” The Company alleged its guidance cut also reflected “new information gained in the quarterly closing process.”

On this news, Molina’s stock price fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Molina’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Molina Healthcare, Inc. class action, go to www.faruqilaw.com/MOH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

A value stock is generally one that trades at a price lower than its fundamental value or what its performance suggests it should be worth.

Having hit record highs at the start of the summer, Sprouts Farmers Market Inc NASDAQ: SFM has spent much of the past few months sliding lower. It’s a tough pill for investors who believed the good times would last forever, but for those of us on the sidelines, there are actually some reasons to get excited. 

Sprouts Farmers Market Today

SFM

Sprouts Farmers Market

$102.74 -1.31 (-1.26%)

As of 10/10/2025 04:00 PM Eastern

52-Week Range$98.75▼

$182.00P/E Ratio21.14

Price Target$177.21

Shares of the specialty grocery chain have fallen more than 40% since June, in what has been an almost one-directional slide. However, after logging 15 days of straight losses, they’ve actually started to stabilize this week, rebounding from Tuesday’s low and holding their ground since. Technical indicators show the selling pressure may finally be easing, and with earnings due later this month, bulls appear to be mounting their first real defense in weeks.

Get Sprouts Farmers Market alerts:

For those who love a bargain, as well as a comeback story, you might not have to look a whole lot further than Sprouts. While the sell-off has been vicious, and the chart does not make for pleasant viewing, there are actually several reasons to consider dipping into the stock ahead of earnings. Here are the top three. 

Reason #1: A Strong Track Record of Beating Expectations
First and foremost is the company’s earnings record. Over multiple quarters now, Sprouts has developed a reputation for consistently outperforming Wall Street’s forecasts on both revenue and earnings. In their most recent report, for example, at the end of July, their GAAP EPS landed a full 9% higher than the consensus, while revenue also came in hot for its second-highest print ever.

These kinds of numbers, as well as the consistent track record, have helped build investor confidence in management’s ability to navigate a volatile grocery and consumer environment. Whether it’s margin discipline, product mix optimization, or store-level efficiency, Sprouts has repeatedly proven its model works, even when broader retail peers have struggled. 

This has made the recent sell-off all the more perplexing, given it doesn’t seem to have been driven by a whole lot more than some profit-taking that got out of hand. Heading into the upcoming earnings report, though, this means expectations are modest, and that works in the company’s favor. With its strong execution record, Sprouts doesn’t need a perfect print to reignite momentum.

Reason #2: Technicals Are Improving After a Steep Slide
The second reason to consider getting involved is the technical setup. After a steady decline since early summer, the setup is beginning to turn green. Sprouts’ RSI reading is near 20, and well below the 30 level that signals oversold conditions, suggesting that sellers may soon be exhausting their momentum.

Tuesday’s bounce from intraday lows marks the first convincing defense of support in weeks, and the stock has managed to hold that level since. The MACD line is also curling higher and looks set for a bullish crossover; another early signal that momentum could be shifting back toward buyers.

If the stock can hold above the key $100 level into next week, while attracting some pre-earnings buying, this week’s low could easily turn into a strong line of support. 

Reason #3: Analysts Still See Big Upside
Sprouts Farmers Market Stock Forecast Today12-Month Stock Price Forecast:
$177.21
72.49% Upside

Moderate Buy
Based on 15 Analyst Ratings

Current Price$102.74High Forecast$200.00Average Forecast$177.21Low Forecast$146.00Sprouts Farmers Market Stock Forecast Details

The final piece of the puzzle is the unwavering analyst support that Sprout commands. Despite the stock’s weakness, analysts are staying optimistic.

Just last week, the team at Evercore ISI maintained its Outperform rating on the company while giving it a fresh price target of $170. From where the stock was trading on Thursday, that’s pointing to a massive 60% upside target.

The Evercore note followed Sprouts’ recent announcement of a $1 billion share repurchase program, a strong vote of confidence from management in the company’s long-term outlook.

That scale of a buyback not only provides downside support but also signals that management views the current share price as undervalued.

Other firms have echoed this view, noting that Sprouts remains well-positioned to benefit from steady grocery demand, continued expansion of its private-label offerings, and the long-term shift toward health-conscious consumer spending.

Bullish Outlook for Q4
Of course, after a slide like that, the company has some work to do to win back investors' confidence. But with earnings approaching, oversold conditions in place, and analysts reiterating their confidence, Sprouts Farmers Market looks primed for a rebound.

The technical picture suggests the worst of the selling pressure may soon be over, while the company’s consistent history of outperforming expectations gives investors a clear reason to get excited. If shares can continue to hold above this week’s lows and momentum indicators confirm a reversal in the coming sessions, Sprouts could be setting up for a strong run into earnings and beyond.

Should You Invest $1,000 in Sprouts Farmers Market Right Now?Before you consider Sprouts Farmers Market, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sprouts Farmers Market wasn't on the list.

While Sprouts Farmers Market currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PubMatic To Contact Him Directly To Discuss Their Options

If you suffered losses in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PubMatic, Inc. (“PubMatic” or the “Company”) (NASDAQ: PUBM) and reminds investors of the October 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that a top DSP buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) that, as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On August 11, 2025, after the market closed, PubMatic released its second quarter 2025 financial report. In its report, PubMatic’s Chief Financial Officer, Steven Pantelick, revealed that the Company’s outlook reflects “a reduction in ad spend from one of [its] top DSP partners.” The Company’s Chief Executive Officer, Rajeev Goel, further revealed that a “top DSP buyer” had “shifted a significant number of clients to a new platform that evaluates inventory differently” causing significant headwinds. Goel stated, in response to the inventory valuation change, the Company would “need to do a better job . . . to prioritize across all the hundreds of billions of daily ad impressions that we have, which subset of those impressions that we send to this DSP.”

On this news, PubMatic’s stock price fell $2.23, or 21.1%, to close at $8.34 per share on August 12, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding PubMatic’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the PubMatic class action, go to www.faruqilaw.com/PUBM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options

If you suffered losses in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) and reminds investors of the October 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (3) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (4) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (5) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (6) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (7) accordingly, Nutex's business and/or financial prospects were overstated; and (8) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 22, 2025, Blue Orca Capital ("Blue Orca") issued a short report on Nutex. The Blue Orca report alleges, among other things, that Nutex faces litigation risk due to its relationship with HaloMD, a third-party vendor that was recently sued for engaging in a "coordinated fraudulent scheme" to take millions from insurance companies on behalf of healthcare billing clients.

Following publication of the Blue Orca report, Nutex's stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025.

On July 24, 2025, Nutex issued a press release responding to the Blue Orca Report, stating that it "strongly disagrees with the allegations in the report" and that it "expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025."

However, after the market closed on August 14, 2025, Nutex announced that it would "delay filing its Form 10-Q for the period ending June 30, 2025", citing "non-cash accounting adjustments related to the treatment of stock-based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings."

When Nutex failed to rebut the allegations of the Blue Orca Report, the Company's stock price fell $18.22 per share, or 16.39%, to close at $92.91 per share on August 15, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Nutex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Nutex Health class action, go to www.faruqilaw.com/NUTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

SummaryToronto-Dominion Bank remains a buy as fundamentals and valuation are attractive despite recent price appreciation and overbought technicals.
TD's robust balance sheet, prudent loan management, and asset diversification support sustainability, profitability, and dividend longevity.
Loan quality is well-managed, capital adequacy is strong, and the bank is insulated from sharp yield drops due to a diversified asset base.
While bullish signals persist, caution is advised as technicals suggest potential for a short-term dip; waiting for a better entry point is recommended.
Aziz Shamuratov /iStock Editorial via Getty Images

Three months after my previous coverage of Toronto-Dominion Bank (NYSE:TD), its price has already increased by 7% and exceeded my target price. At first glance, it may warrant a downgrade. But as I

Analyst’s Disclosure:I/we have a beneficial long position in the shares of td either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

If it's strong income and growth you're after, you may want to consider dividend-paying exchange-traded funds. We can look at high-yield dividend funds, which target companies with above-average yields in hot sectors such as consumer staples and telecommunications.

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced. Many promising companies now trade at a fraction of their previous highs, while investors pour money into artificial intelligence (AI) names trading at record multiples.

That gap creates opportunity. Several healthcare innovators are approaching pivotal stages of development, yet their share prices still reflect caution rather than potential. These four healthcare stocks stand out as timely buys in a market that has overlooked their progress.

Image source: Getty Images.

Commercial momentum building
Crispr Therapeutics (CRSP -2.44%) and Vertex Pharmaceuticals (VRTX -1.68%) developed Casgevy, the first gene-editing treatment approved for sickle cell disease and beta-thalassemia, two inherited blood disorders.

Vertex reported $30 million in Casgevy sales in the second quarter of 2025, a sharp uptick from prior quarters, showing the drug is starting to gain traction in the marketplace. Crispr receives 40% of the program's profits through its partnership with Vertex.

By mid-2025, 75 hospitals and clinics worldwide had been cleared to administer Casgevy, and approximately 115 patients had begun the treatment process. As more centers gain experience, patient numbers and sales are expected to grow through 2025 and 2026.

Outside of Casgevy, Crispr is working on several new treatments it fully owns, such as CTX112, a cell-based therapy in early testing for cancer and immune diseases. Results from CTX112 or other key pipeline candidates in late 2025 could provide a boost to the stock if the data show clear progress.

Late-stage catalysts approaching
Intellia Therapeutics (NTLA -3.81%) is advancing two CRISPR gene-editing programs toward key readouts. It recently completed enrollment in its Phase 3 study for hereditary angioedema, a rare disease that causes sudden swelling attacks, using a treatment called lonvoguran ziclomeran (NTLA-2002). Topline results are expected in the first half of 2026, with a regulatory filing planned later that year.

Intellia is also pushing forward with its program for ATTR amyloidosis, a disease in which abnormal proteins build up and damage the heart and nerves, using a treatment called nex-z (NTLA-2001). A pivotal trial is underway, and earlier testing showed that a single dose can reduce the TTR protein by approximately 91% in many patients, with data showing sustained reductions over time.

If both programs succeed, Intellia could become one of the first companies to win approval for a single-dose, in vivo CRISPR therapy (where gene editing happens directly inside the body) -- a potential breakthrough that could lift investor expectations and reset how gene-editing companies are valued.

Platform plays with pharma validation
Recursion Pharmaceuticals (RXRX -9.98%) runs a drug discovery platform powered by AI and backed by big pharma partnerships such as Sanofi, Roche, and Bayer. In its latest results, the company pulled in $19.2 million in revenue -- primarily from collaborations.

Several clinical trial updates are expected later in 2025. If those trials show its AI-discovered drugs perform well in patients, the market may begin valuing its individual programs more favorably -- and that could unlock significant upside for the stock.

Viking Therapeutics (VKTX -4.00%) is advancing VK2735, a dual GLP-1/GIP agonist, through late-stage development for obesity. In its mid-stage study, the injectable version produced up to 14.7% average weight loss after 13 weeks and is now being tested in a large late-stage trial across obesity and type 2 diabetes populations.

The stock declined in August 2025 after results from the oral formulation showed higher dropout rates caused by gastrointestinal side effects from rapid dose escalation. The findings reflected how the drug was given, not an underlying problem with the compound.

With a slower titration schedule, tolerability could improve meaningfully. Both the injectable and oral versions remain key to Viking's obesity strategy, positioning the company to compete in a market expected to exceed $100 billion in annual sales.

George Budwell has positions in CRISPR Therapeutics and Viking Therapeutics and has the following options: long January 2027 $100 calls on Viking Therapeutics and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends CRISPR Therapeutics, Intellia Therapeutics, and Vertex Pharmaceuticals. The Motley Fool recommends Roche Holding AG and Viking Therapeutics. The Motley Fool has a disclosure policy.

Top Ancillary Cannabis Stocks to Watch in October 2025
The U.S. cannabis industry continues to grow rapidly as legalization momentum spreads across new states. According to recent data, the market is projected to exceed $35 billion in annual sales by 2025. Additionally, analysts expect the industry to reach over $70 billion by 2030 as federal reform progresses. Last week, renewed discussions in Congress surrounding cannabis rescheduling lifted investor optimism. The Department of Health and Human Services’ recommendation to reclassify cannabis also fueled market speculation. As a result, many ancillary stocks—those supporting growers with equipment, nutrients, and hydroponic systems—saw a spike in trading activity. These companies remain essential for industry expansion, offering investors exposure without the risks of direct plant handling.

However, despite the growing optimism, traders must apply disciplined technical analysis and proper risk management. Chart patterns, moving averages, and support zones can help identify ideal entry levels. Furthermore, setting clear stop losses helps protect capital during market volatility. Ancillary cannabis stocks can experience sharp price swings following regulatory headlines. Therefore, traders should look for confirmation signals before entering positions. Diversifying across multiple plays also helps reduce risk exposure. With legalization efforts gaining traction and cultivation demand increasing, technical setups in this sector may present strong short-term opportunities. By combining trend analysis with sound strategy, investors can trade these stocks more confidently this week.

Ancillary Cannabis Stocks Powering the Industry’s Next Wave
As the cannabis sector evolves, ancillary companies continue to play a vital role in supporting its rapid growth. These firms provide essential cultivation products, lighting systems, nutrients, and technologies that enable producers to operate efficiently without touching the plant directly. In 2025, the U.S. cannabis market is projected to surpass $35 billion in annual sales, with continued expansion expected as more states move toward legalization. Ancillary companies benefit from this trend, offering investors diversified exposure and lower regulatory risk.

This October, three standout ancillary cannabis stocks are worth watching—GrowGeneration Corp. (GRWG), Hydrofarm Holdings Group Inc. (HYFM), and Scotts Miracle-Gro Company (SMG). Each plays a unique role in the cannabis supply chain. They also demonstrate varying degrees of financial recovery as the industry rebounds from previous oversupply pressures. Below is a closer look at their operations, market presence, and recent financial performance.

[Read More] Top 3 Canadian Cannabis Stocks to Watch in October 2025

October 2025 Watchlist: GrowGeneration, Hydrofarm, and Scotts Miracle-Gro Lead Ancillary Cannabis Gains

GrowGeneration Corp. (NASDAQ: GRWG)
Hydrofarm Holdings Group Inc. (NASDAQ: HYFM)
Scotts Miracle-Gro Company (NYSE: SMG)

GrowGeneration Corp. (GRWG)
GrowGeneration operates one of the largest hydroponic and organic gardening supply chains in the United States. It does not own dispensaries but serves as a crucial supplier for licensed cultivators and home growers. The company’s biggest footprint lies in California, Colorado, Florida, Oregon, and the Northeastern U.S. With over 60 retail locations nationwide, GrowGeneration provides a full range of cultivation essentials, including lighting systems, nutrients, soils, and environmental controls.

The company has successfully built proprietary brands such as CharCoir, Drip Hydro, and Ion LED, which now make up a significant share of its product portfolio. Through a mix of e-commerce and brick-and-mortar stores, it continues to expand market reach and deepen relationships with commercial growers. As legalization momentum grows across the country, GrowGeneration remains strategically positioned as a key retail and distribution partner for the cannabis cultivation industry.

Financially, GrowGeneration has shown early signs of stabilization in 2025. In its latest quarter, the company reported approximately $41 million in net sales, reflecting gradual improvement from earlier quarters. Gross margins improved to around 28%, supported by higher sales of proprietary products and better cost control. Operating expenses have decreased as management streamlines operations and consolidates store performance.

The net loss for the quarter narrowed to under $5 million, a significant improvement compared to prior periods. Importantly, GrowGeneration holds minimal debt and maintains roughly $50 million in cash and marketable securities, giving it flexibility to invest in growth. While adjusted EBITDA remains slightly negative, the trend is positive. The company continues focusing on higher-margin categories and private-label brands to drive profitability into 2026.

[Read More] 3 Cannabis REITs Leading the Marijuana Stock Market in October 2025

Hydrofarm Holdings Group Inc. (HYFM)
Hydrofarm Holdings designs, manufactures, and distributes hydroponic and controlled-environment agricultural products. Like GrowGeneration, Hydrofarm does not operate dispensaries but plays a critical role in the supply chain. It serves commercial cultivators, indoor farmers, and greenhouses across the United States and Canada. The company operates several large distribution centers and has a diverse product catalog that includes lighting systems, nutrient lines, climate controls, and grow media.

Hydrofarm’s key competitive strength lies in its proprietary and acquired product brands. It has developed a reputation among professional growers for high-efficiency lighting and nutrient delivery systems. Despite challenges in recent years due to industry oversupply and retailer consolidation, Hydrofarm continues to maintain a loyal customer base. As the cannabis market stabilizes, the company is expected to benefit from renewed capital investment by cultivators expanding capacity.

On the financial side, Hydrofarm’s most recent results showed continued operational challenges but also early restructuring benefits. The company reported a per-share loss of around $3.60, compared to a loss of roughly $2.80 in the same quarter last year. Revenues came in lower year over year due to weaker order volumes from commercial growers, yet cost reductions offset part of the shortfall. Gross margins remained in the mid-teens at about 15%, reflecting pricing pressure and discounting to clear inventory.

Hydrofarm carries moderate long-term debt, but liquidity ratios indicate manageable short-term solvency. Management has been actively renegotiating supplier agreements and optimizing its logistics network to improve profitability. Although profitability remains elusive, analysts expect a gradual recovery as the market normalizes and Hydrofarm’s new product lines gain traction. The next few quarters will be crucial for the company to demonstrate consistent cash-flow improvements.

[Read More] Top Marijuana Stocks for October 2025: U.S. MSOs Showing Strength and Growth Potential

Scotts Miracle-Gro Company (SMG)
Scotts Miracle-Gro is a well-known leader in lawn, garden, and hydroponic solutions, giving investors a diversified way to gain cannabis exposure. Its Hawthorne Gardening Company division serves as the cannabis industry’s primary link. Through Hawthorne, Scotts provides hydroponic systems, LED lighting, nutrients, and environmental control technologies to large commercial cultivators. While the company does not own or manage dispensaries, its products are deeply embedded in the cultivation supply chain.

Scotts’ largest cannabis-related presence is in California and other high-growth U.S. states where commercial cultivation has scaled significantly. The parent company’s broader consumer gardening business helps buffer Hawthorne’s cyclical performance. As a result, Scotts offers stability and long-term potential even during periods of market consolidation. Hawthorne has also invested heavily in research and partnerships focused on sustainability and water-efficient growing systems — areas gaining traction among environmentally focused growers.

Financially, Scotts Miracle-Gro remains one of the strongest ancillary cannabis plays in the market. The company recently reaffirmed its full-year 2025 outlook with continued sales growth in both consumer and Hawthorne divisions. The Hawthorne segment experienced rising demand for LED grow lighting and advanced nutrient systems, signaling recovery from earlier slowdowns. Gross margins improved year over year as higher volumes offset prior inventory markdowns.

Scotts continues to generate robust free cash flow, which supports dividend payments and additional R&D investment. While the cannabis segment represents a smaller percentage of total revenue, it offers meaningful upside as federal reform advances. The company’s diversified structure provides resilience in volatile markets, making SMG an appealing ancillary stock for investors seeking stability with exposure to cannabis-driven growth.

Investing Beyond the Plant
Ancillary cannabis companies like GrowGeneration, Hydrofarm, and Scotts Miracle-Gro remain key beneficiaries of the U.S. cannabis industry’s expansion. They provide the tools and technology enabling cultivators to produce efficiently and profitably. As legalization progresses, demand for high-quality growing supplies and equipment should continue to rise.

From a technical standpoint, traders should monitor support and resistance levels closely, especially as volatility increases in the broader market. Proper risk management — including defined stop levels and position sizing — is essential when trading or investing in these volatile names. With the cannabis industry poised for another wave of growth, these three ancillary stocks offer investors diversified exposure to one of the most promising sectors heading into 2026.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in WZZAF over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options

If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process.

On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline.

As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Cytokinetics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Cytokinetics, Incorporated class action, go to www.faruqilaw.com/CYTK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Analyst’s Disclosure:I/we have a beneficial long position in the shares of JEPQ, QYLD, NVDA, GOOG, AMZN, TSLA, META, AAPL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quantum Corporation To Contact Him Directly To Discuss Their Options

If you suffered losses in Quantum Corporation between November 15, 2024 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Quantum Corporation (“Quantum Corporation” or the “Company”) (NASDAQ: QMCO) and reminds investors of the November 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Quantum Corporation improperly recognized revenue during the fiscal year ended March 31, 2025; (2) Quantum Corporation would therefore need to restate its previously filed financial statements for the fiscal third quarter ended December 31, 2024; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On June 30, 2025, Quantum disclosed that it would be unable to timely file its annual financial report for the fiscal year 2025 as it is “reviewing its accounting related to certain revenue contracts as well as the application of standalone selling price under applicable accounting standards.”

On this news, Quantum’s stock price fell $1.00, or 10.03%, to close at $8.97 per share on June 30, 2025, thereby injuring investors.

Then, on August 8, 2025, Quantum announced that its third quarter 2024 financial statements “should no longer be relied upon” due to “deficiencies in the Company’s internal control over financial reporting and the Company’s disclosure controls and procedures that constituted material weaknesses.” The Company further disclosed that the affected financial statements would be restated to show a new decrease of approximately $3.9 million in revenue.

On this news, Quantum’s stock price fell $0.14, or 1.79%, to close at $7.66 per share on August 11, 2025.

Then, on August 18, 2025, Quantum disclosed that its CEO would be resigning from the role after only five months in the position.

On this news, Quantum’s stock price fell $0.61, or 8.2%, to close at $6.83 per share on August 19, 2025, thereby injuring investors further.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Quantum Corporation’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Quantum Corporation class action, go to www.faruqilaw.com/QMCO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).

If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Charter To Contact Him Directly To Discuss Their Options

If you suffered losses in Charter between July 26, 2024 and July 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Charter Communications, Inc. (“Charter” or the “Company”) (NASDAQ: CHTR) and reminds investors of the October 13, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the impact of the ACP end was a material event the Company was unable to manage or promptly move beyond; (ii) the ACP end was actually having a sustaining impact on Internet customer declines and revenue; (iii) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (iv) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (v) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (iv) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about the Company’s business, operations, outlook during the Class Period.

On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024, when adjusted to remove the prior year's impact of the end of the Affordable Connectivity Program. The Company's total video customers also decreased by 80,000.

On this news, Charter's stock price fell $70.25 per share, or 18.5%, to close at $309.75 per share on July 25, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Charter’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Charter Communications class action, go to www.faruqilaw.com/CHTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options

If you suffered losses in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) and reminds investors of the October 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD announced revised guidance. Among other metrics, LifeMD stated that it was expecting total revenue in the range of $250 to $255 million, compared with previous guidance of $268 to $275 million.

On this news, LifeMD's stock plummeted 44.8% on August 6, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding LifeMD’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the LifeMD class action, go to www.faruqilaw.com/LFMD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options

If you suffered losses in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and reminds investors of the November 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) the delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On May 27, 2025, Savara issued a press release "announc[ing] that the Company received [a refusal to file] letter from the FDA for the [Biologics License Application] of MOLBREEVI as a therapy to treat patients with autoimmune PAP."

On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Savara’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Savara class action, go to www.faruqilaw.com/SVRA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

If you suffered losses in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On June 10, 2025, Unicycive issued a press release "announcing an update on its [NDA] for [OLC] to treat hyperphosphatemia in patients with [CKD] on dialysis." Therein, the Company disclosed that the FDA "had identified deficiencies in cGMP [current good manufacturing practice] compliance at a third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."

On this news, Unicycive's stock price fell $3.68 per share, or 40.89%, to close at $5.32 per share on June 10, 2025.

Then, on June 30, 2025, Unicycive issued a press release announcing that the FDA had issued a Complete Response Letter for the OLC NDA, citing the previously identified cGMP deficiencies at the third-party subcontractor of its CDMO.

On this news, Unicycive's stock price fell $2.03 per share, or 29.85%, to close at $4.77 per share on June 30, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Unicycive’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Unicycive Therapeutics class action, go to www.faruqilaw.com/UNCY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

SummaryGLD and gold in general have surged higher in recent weeks. But gold is cyclical.I prefer to express my gold position through options alone, or via an option collar. I provide timely insight on those here.The "golden collar" involves buying puts and selling covered calls on GLD to set profit and loss boundaries after the recent rally.This is as good a time as I've seen for investors to learn how to use options responsibly and with confidence, given these unique market conditions.Looking for more investing ideas like this one? Get them exclusively at Sungarden Investors Club. Learn More » adventtr/E+ via Getty Images

When it comes to investing in gold, including via funds like SPDR Gold Shares ETF (NYSEARCA:GLD)...I don't. OK, let me explain that.

Maybe you remember those great commercials for Dos Equis beer featuring a character

Analyst’s Disclosure:I/we have a beneficial long position in the shares of GLD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I own puts and calls, considering a collar soon.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

SummaryA new trade war threat from President Trump just reshuffled the entire stock market.I discuss what the big gift to dividend investors is.I also share how I am taking advantage of President Trump's gift.Looking for a portfolio of ideas like this one? Members of High Yield Investor get exclusive access to our subscriber-only portfolios. Learn More » LPETTET/iStock Unreleased via Getty Images

President Donald Trump just gave a much-needed boost to dividend investors. In this article, I will detail what that gift is and share how I am positioning my portfolio to take advantage of it.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of OKE, GLD, EPD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have a beneficial long position in the shares of TSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Semler Scientific To Contact Him Directly To Discuss Their Options

If you suffered losses in Semler Scientific between March 10, 2021 and April 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific, Inc. (“Semler Scientific” or the “Company”) (NASDAQ: SMLR) and reminds investors of the October 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Semler Scientific did not disclose a material investigation by the United States Department of Justice (the “DOJ”) into violations of the False Claims Act, while discussing possible violations of the False Claims (and aggressive DOJ enforcement thereof) in hypothetical terms; and (2) as a result, defendants public statements were materially false and/or misleading at all relevant times.

After trading hours on February 28, 2025, Semler Scientific filed with the SEC its 2024 annual report on Form 10-K. The annual report disclosed that on February 11, 2025, Semler Scientific "began initial settlement discussions with DOJ [(the United States Department of Justice)], but ceased initial discussions on that date. Accordingly, there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages. [Semler Scientific] does not believe the amount of loss can be reasonably estimated."

On this news, Semler Scientific's stock fell over 9% on the next trading day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Semler Scientific’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Semler Scientific class action, go to www.faruqilaw.com/SMLR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d516bf4b-fab7-416f-a74a-ea4437d5b4b3

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The two companies now have a partnership to build massive data centers for artificial intelligence (AI) computing.

Computing capacity is everything. At least, that is what CEO Sam Altman says about OpenAI. The artificial intelligence (AI) disruptor has been signing deals to help finance its increasing need for data centers to run its ChatGPT systems, which are growing rapidly and now have over 700 million weekly active users.

The largest of these deals is with Nvidia (NVDA -4.84%). Nvidia will invest $100 billion incrementally into OpenAI, which will then spend the money on Nvidia chips to build 10 gigawatts or more of AI data centers. This could not only be a lucrative investment for Nvidia, but should lead to a huge revenue boost for the rest of the decade.

Today, Nvidia has the largest market cap in the world, at $4.6 trillion as of this writing. Will this new OpenAI deal catalyze Nvidia to become the world's first $10 trillion stock? Let's take a closer look at the deal and find out.

A $100 billion partnership
On Sept. 22, OpenAI and Nvidia jointly announced a potentially revolutionary strategic partnership. OpenAI is not like the giant cloud providers such as Alphabet, which spent years building infrastructure suited for AI. OpenAI is a large company, but its still not profitable and it needs a ton of capital to make its AI vision come true.

Nvidia is the key supplier of graphics processing units (GPUs) for AI data centers. Without the big tech balance sheets, OpenAI has gotten creative with its financing structure. Nvidia is going to slowly invest around $100 billion into OpenAI, who will then take that cash and build data centers with Nvidia computer chips. This could represent millions of GPUs purchased from Nvidia to build 10 gigawatts of capacity.

It is estimated that current data center capacity in the United States is just over 50 gigawatts. This means the proposed spending from OpenAI utilizing Nvidia GPUs could end up being a 20% boost to the total data center footprint in the United States today. This is a gargantuan scale that should put the $100 billion and 10-gigawatt claims in proper context.

Image source: Nvidia.

Nvidia's revenue potential
The AI data center boom already turned Nvidia into the largest company in the world by market cap. Its revenue over the last 12 months was $165 billion, which it turned into $86.6 billion in bottom-line net income.

OpenAI is not going to add $100 billion to Nvidia's top line in 2026. However, through 2030, it could incrementally add tens of billions to Nvidia's annual revenue figures, which would be impactful versus its $165 billion current level. Remember that OpenAI is not Nvidia's only customer: It sells to the likes of Meta Platforms, Microsoft, and Amazon for their own data center expansion plans.

We shouldn't forget the investment in OpenAI, either. Nvidia's $100 billion investment into OpenAI may not turn into trillions of dollars in value, but it could be quite lucrative if OpenAI turns into a trillion-dollar business itself and Nvidia owns 10% of the company (as an example, 10% isn't an exact figure).

NVDA PE Ratio data by YCharts

Will Nvidia hit $10 trillion?
OpenAI is setting the standard in AI infrastructure spending, and it is not low. Other competitors will need to raise their spending in order to match what OpenAI is building to catch up in the AI race.

All this will lead to more spending on Nvidia computer chips. If the company has a market cap of $4.6 trillion today versus $165 billion in revenue, it will likely need to hit $300 billion in annual revenue or more to hit a $10 trillion value.

Today, Nvidia has a net income margin of 53%. If that margin is maintained with revenue of $350 billion that arrives because of huge spending levels from OpenAI and others, Nvidia will have $185.5 billion in net income at some point within this decade. That would give it an expensive price-to-earnings ratio (P/E) of 54, but that is not far off from Nvidia's current P/E of 53.

It may seem unlikely, but there is a chance that OpenAI's deal spurs Nvidia to reach a market cap of $10 trillion by 2030. Just don't go investing in the stock thinking it is guaranteed to happen tomorrow.

Brett Schafer has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.